Cargando…

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation

INTRODUCTION: Alzheimer’s disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible for significant burden on caregivers and healthcare systems. In this study, data from the large phase III CLARITY AD trial were used to estimate the s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Igarashi, Ataru, Azuma, Mie Kasai, Zhang, Quanwu, Ye, Weicheng, Sardesai, Aditya, Folse, Henri, Chavan, Ameya, Tomita, Kiyoyuki, Tahami Monfared, Amir Abbas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310671/ https://www.ncbi.nlm.nih.gov/pubmed/37188886 http://dx.doi.org/10.1007/s40120-023-00492-7

Ejemplares similares

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Linguistic and Psychometric Validation of the Cognition Bolt-On Version of the Japanese EQ-5D-5L for the Elderly
por: Igarashi, Ataru, et al.
Publicado: (2023)

Staging Disease Severity Using the Alzheimer’s Disease Composite Score (ADCOMS): A Retrospective Data Analysis
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Correction to: Staging Disease Severity Using the Alzheimer’s Disease Composite Score (ADCOMS): A Retrospective Data Analysis
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Alzheimer’s Disease: Epidemiology and Clinical Progression
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

The Humanistic and Economic Burden of Alzheimer's Disease
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Understanding Barriers Along the Patient Journey in Alzheimer’s Disease Using Social Media Data
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Assessing the Clinical Meaningfulness of the Alzheimer’s Disease Composite Score (ADCOMS) Tool
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer’s Disease
por: Morin, Peter J., et al.
Publicado: (2023)

Economic Burden of Alzheimer’s Disease Dementia in Japan
por: Ikeda, Shunya, et al.
Publicado: (2021)

Estimating Transition Probabilities Across the Alzheimer’s Disease Continuum Using a Nationally Representative Real-World Database in the United States
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

A Systematic Review of Clinical Practice Guidelines for Alzheimer’s Disease and Strategies for Future Advancements
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Factors Driving the Transition of Alzheimer’s Disease Patients to Institutional Long-term Care
por: Davila, Heather, et al.
Publicado: (2021)

Treatment Preference for Alzheimer’s Disease: A Multicriteria Decision Analysis with Caregivers, Neurologists, and Payors
por: Dranitsaris, George, et al.
Publicado: (2022)

Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists
por: Dranitsaris, George, et al.
Publicado: (2023)

Reply: Unblinding in the lecanemab trial in Alzheimer’s disease
por: Hardy, John, et al.
Publicado: (2023)

Lecanemab: A hope in the management of Alzheimer’s disease
por: Thakkar, Nandita, et al.
Publicado: (2023)

Impact of the Severity of Alzheimer’s Disease on the Quality of Life, Activities of Daily Living, and Caregiving Costs for Institutionalized Patients on Anti-Alzheimer Medications in Japan
por: Ashizawa, Takumi, et al.
Publicado: (2021)

Clinical Staging of Alzheimer’s Disease: Concordance of Subjective and Objective Assessments in the Veteran’s Affairs Healthcare System
por: Morin, Peter, et al.
Publicado: (2022)

Lecanemab reduces brain amyloid-β and delays cognitive worsening
por: Knopman, David S.
Publicado: (2023)

Reply: Lecanemab: turning point, or status quo? An ethics perspective
por: Hardy, John, et al.
Publicado: (2023)

Modeling long-term health and economic implications of new treatment strategies for Parkinson’s disease: an individual patient simulation study
por: Chandler, Conor, et al.
Publicado: (2021)

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
por: Jönsson, Linus, et al.
Publicado: (2023)

Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2019)

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
por: Quon, Peter L., et al.
Publicado: (2019)

Rule-Based Identification of Individuals with Mild Cognitive Impairment or Alzheimer’s Disease Using Clinical Notes from the United States Veterans Affairs Healthcare System
por: Aguilar, Byron J., et al.
Publicado: (2023)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
por: Honig, Lawrence S., et al.
Publicado: (2023)

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
por: Verger, Antoine, et al.
Publicado: (2023)

Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
por: Qiao, Yue, et al.
Publicado: (2023)

Burden of illness associated with pneumococcal infections in Japan - a targeted literature review
por: Igarashi, Ataru, et al.
Publicado: (2021)

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review
por: Chowdhury, Selia, et al.
Publicado: (2023)

Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective
por: Volloch, Vladimir, et al.
Publicado: (2023)

A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan
por: Nakajima, Atsushi, et al.
Publicado: (2021)

Comparison of the effect of lemborexant and other insomnia treatments on driving performance: a systematic review and meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Code des sociétés: dispositions générales, sociétés civiles, sociétés commerciales, sociétés cotées en bourse, sociétés particulières
por: France
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_jn2a5vn5a6qc00rc5ddhn7qpih